ArticleFrontiers in immunology2026
Visual prognosis of Behçet's uveitis patients in China and its associated factors.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Behçet's disease (BD) is a chronic, relapsing, multisystem inflammatory disorder, with ocular involvement being a major cause of irreversible visual impairment. Behçet's uveitis (BU) often presents as bilateral, recurrent, non-granulomatous panuveitis with occlusive retinal vasculitis. Despite advances in immunosuppressive and biologic therapies, long-term visual outcomes remain variable, and factors associated with poor prognosis, particularly in Chinese populations, are not well defined. Methods: We conducted a retrospective cohort study of 153 Chinese patients (268 eyes) with BU at Peking Union Medical College Hospital from February 2003 to February 2023. Clinical records, ocular examinations, and systemic manifestations were reviewed. The primary endpoint was severe visual impairment (best-corrected visual acuity [BCVA] <20/200) at the final follow-up. Secondary endpoints included ocular complications and their impact on visual outcomes. Kaplan-Meier survival analysis and mixed-effects logistic regression (accounting for inter-eye correlation) were used to evaluate risk factors for poor visual prognosis. Results: Among the cohort, 77.8% were male, and bilateral involvement occurred in 84.3%. Median follow-up was 30 months. Panuveitis was the predominant form (90.3%), and cataract (64.9%) and macular edema (63.1%) were the most common complications. At final follow-up, 25.4% of eyes had BCVA <20/200. Kaplan-Meier analysis showed cumulative risk of severe visual loss of 3.5% at 1 year, 11.0% at 2 years, 19.2% at 5 years, and 41.4% at 10 years. Male patients experienced visual impairment earlier than females. Mixed-effects logistic regression identified macular damage (p=0.027, OR = 3.70) and optic nerve atrophy (p<0.001, OR = 6.47) as significant predictors of poor visual outcomes, while complete-type BD showed a trend toward association (p=0.072, OR = 2.00). Systemic disease severity was not significantly associated with visual prognosis. Conclusion: In this Chinese cohort with BU, irreversible ocular structural damage, particularly macular damage and optic nerve atrophy, was the primary determinant of long-term visual outcomes. Systemic disease severity had limited predictive value. Despite improvements compared with historical data, these findings highlight the critical importance of early recognition and effective management of posterior segment inflammation to prevent permanent visual impairment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.